All Recalls

95,064 total recalls in our database

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Apr 29, 2026 Prescription Drugs Nationwide View Details →

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

Apr 23, 2026 Prescription Drugs Nationwide View Details →

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Apr 24, 2026 Prescription Drugs Nationwide View Details →

Medline has identified issues related to calibration of the equipment used to sterilize and package the devices. All products were exposed to the validated sterilization and packaging cycles; however, the identified calibration issues have the potential to impact the sterility assurance level (SAL) of the Recalled Products.

Jan 7, 2026 Other Medical Devices Nationwide View Details →
🏥 Medical Devices Class I - Dangerous

Medline has identified issues related to calibration of the equipment used to sterilize and package the devices. All products were exposed to the validated sterilization and packaging cycles; however, the identified calibration issues have the potential to impact the sterility assurance level (SAL) of the Recalled Products.

Jan 7, 2026 Other Medical Devices Nationwide View Details →
🏥 Medical Devices Class I - Dangerous

Medline has identified issues related to calibration of the equipment used to sterilize and package the devices. All products were exposed to the validated sterilization and packaging cycles; however, the identified calibration issues have the potential to impact the sterility assurance level (SAL) of the Recalled Products.

Jan 7, 2026 Other Medical Devices Nationwide View Details →

Medline has identified issues related to calibration of the equipment used to sterilize and package the devices. All products were exposed to the validated sterilization and packaging cycles; however, the identified calibration issues have the potential to impact the sterility assurance level (SAL) of the Recalled Products.

Jan 7, 2026 Other Medical Devices Nationwide View Details →

Medline has identified issues related to calibration of the equipment used to sterilize and package the devices. All products were exposed to the validated sterilization and packaging cycles; however, the identified calibration issues have the potential to impact the sterility assurance level (SAL) of the Recalled Products.

Jan 7, 2026 Infusion Pumps Nationwide View Details →

Some defibrillators serviced between July 2023 through November 2025 were serviced without objective evidence that a Performance Inspection Procedure (PIP) was conducted, and the inability to perform the device's intended use may result in potential harms such as delays or inability to provide therapy.

Apr 13, 2026 Other Medical Devices Nationwide View Details →